TCIM
IBB icon

TIAA CREF Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

TIAA CREF Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-243,053
Closed -$26M – 3043
2017
Q4 		$26M Sell
243,053
-55,057
-18% -$5.89M 0.02% 669
2017
Q3 		$33.1M Buy
298,110
+142,773
+92% +$15.3M 0.02% 569
2017
Q2 		$16.1M Buy
+155,337
New +$15.3M 0.01% 862
2017
Q1 		– Sell
-271,794
Closed -$24M – 3083
2016
Q4 		$24M Buy
+271,794
New +$24.7M 0.02% 682

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
N
Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TIAA CREF Investment Management's IBB Position: Q1 2018 in Review

TIAA CREF Investment Management sold out of iShares Biotechnology ETF (IBB) in Q1 2018, closing a stake of 243,053 shares — an estimated $26M sold.

TIAA CREF Investment Management first reported a position in IBB in Q4 2016 and held it in 4 quarters. The position peaked at $33.1M in Q3 2017. 607 funds tracked by Wall St. Rank hold IBB as of Q1 2018.

  • TIAA CREF Investment Management reported no remaining iShares Biotechnology ETF position as of Q1 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 243,053 iShares Biotechnology ETF shares in Q1 2018, an estimated $26M.
  • TIAA CREF Investment Management first reported a position in iShares Biotechnology ETF in Q4 2016 and held it in 4 quarters.
  • TIAA CREF Investment Management's iShares Biotechnology ETF position peaked at $33.1M in Q3 2017.
  • 607 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2018.

Based on TIAA CREF Investment Management's 13F filing for Q1 2018, filed 14 May 2018.